Afatinib, as an irreversible second-generation EGFR-TKI, showed significant improvement in PFS and ORR in EGFR-sensitive mutation NSCLC when compared with gefitinib, but there was no significant difference in OS (Paz-Ares et al., 2017). This evidence concerns the gene EGFR and non-small cell lung carcinoma.